JP2009532372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532372A5 JP2009532372A5 JP2009503119A JP2009503119A JP2009532372A5 JP 2009532372 A5 JP2009532372 A5 JP 2009532372A5 JP 2009503119 A JP2009503119 A JP 2009503119A JP 2009503119 A JP2009503119 A JP 2009503119A JP 2009532372 A5 JP2009532372 A5 JP 2009532372A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- agent according
- hydrogen
- agent
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74402106P | 2006-03-31 | 2006-03-31 | |
| PCT/US2007/063288 WO2007117791A2 (en) | 2006-03-31 | 2007-03-05 | Combination treatment of metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009532372A JP2009532372A (ja) | 2009-09-10 |
| JP2009532372A5 true JP2009532372A5 (https=) | 2010-04-22 |
Family
ID=38581719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503119A Pending JP2009532372A (ja) | 2006-03-31 | 2007-03-05 | 代謝障害の併用治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8338480B2 (https=) |
| EP (1) | EP2001461A4 (https=) |
| JP (1) | JP2009532372A (https=) |
| KR (1) | KR20080106455A (https=) |
| CN (1) | CN101410105A (https=) |
| AU (1) | AU2007235145B2 (https=) |
| CA (1) | CA2647258A1 (https=) |
| IL (1) | IL194189A0 (https=) |
| MX (1) | MX2008012506A (https=) |
| NZ (1) | NZ571118A (https=) |
| WO (1) | WO2007117791A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03011558A (es) * | 2001-06-12 | 2004-03-26 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
| WO2006127133A2 (en) | 2005-04-01 | 2006-11-30 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US20090176885A1 (en) * | 2006-02-02 | 2009-07-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| JP5766947B2 (ja) * | 2007-09-07 | 2015-08-19 | チルドレンズ ホスピタル メディカル センター | 臨床サンプルにおける分泌性のルイス抗原およびシアル化抗原のレベルの疾患リスクの予測指標としての使用 |
| JP5496913B2 (ja) * | 2008-01-15 | 2014-05-21 | ウェルスタット セラピューティクス コーポレイション | 代謝異常の治療のための化合物 |
| EP2085120A1 (en) * | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| JP5339545B2 (ja) * | 2008-03-13 | 2013-11-13 | ウェルスタット セラピューティクス コーポレイション | 尿酸を減少させる化合物及び方法 |
| EP2451462B1 (en) | 2009-07-06 | 2017-09-06 | Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
| WO2012033720A1 (en) | 2010-09-08 | 2012-03-15 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
| US9805725B2 (en) | 2012-12-21 | 2017-10-31 | Dolby Laboratories Licensing Corporation | Object clustering for rendering object-based audio content based on perceptual criteria |
| US10626460B2 (en) | 2013-02-21 | 2020-04-21 | Children's Hospital Medical Center | Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease |
| JP6553375B2 (ja) * | 2014-06-24 | 2019-07-31 | 花王株式会社 | Ｕｃｐ−１発現促進剤 |
| US10758519B2 (en) | 2014-06-24 | 2020-09-01 | Kao Corporation | UCP-1 expression promoter |
| WO2015199097A1 (ja) * | 2014-06-24 | 2015-12-30 | 花王株式会社 | Ｕｃｐ－１発現促進剤 |
| JP6660668B2 (ja) * | 2014-06-24 | 2020-03-11 | 花王株式会社 | Ｕｃｐ−１発現促進剤 |
| WO2016176484A1 (en) | 2015-04-28 | 2016-11-03 | Children's Hospital Medical Center | Use of oligosaccharide compositions to enhance weight gain |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG59988A1 (en) * | 1987-09-04 | 1999-02-22 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| MXPA03011201A (es) | 2001-06-07 | 2004-02-26 | Lilly Co Eli | Moduladores de receptores activados por proliferadores de persoxisomas. |
| MXPA03011558A (es) * | 2001-06-12 | 2004-03-26 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
| CA2502297C (en) | 2002-11-01 | 2011-12-13 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| MXPA05008600A (es) | 2003-02-13 | 2005-11-04 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
| CN1774244A (zh) * | 2003-04-15 | 2006-05-17 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| CN1777576A (zh) | 2003-04-22 | 2006-05-24 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| MXPA05011592A (es) | 2003-04-30 | 2005-12-15 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de trastornos metabolicos. |
| DE602004031954D1 (de) * | 2003-08-20 | 2011-05-05 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
| WO2006127133A2 (en) | 2005-04-01 | 2006-11-30 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| FR2887881B1 (fr) | 2005-07-01 | 2009-10-09 | Pierre Fabre Medicament Sa | Inhibiteurs de proteines kinases |
| EP1976377A4 (en) | 2006-01-25 | 2010-06-23 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| NZ569729A (en) | 2006-01-25 | 2011-07-29 | Wellstat Therapeutics Corp | Compounds for the treatment of metabolic disorders |
-
2007
- 2007-03-05 KR KR1020087023632A patent/KR20080106455A/ko not_active Ceased
- 2007-03-05 MX MX2008012506A patent/MX2008012506A/es not_active Application Discontinuation
- 2007-03-05 EP EP07757896A patent/EP2001461A4/en not_active Withdrawn
- 2007-03-05 WO PCT/US2007/063288 patent/WO2007117791A2/en not_active Ceased
- 2007-03-05 AU AU2007235145A patent/AU2007235145B2/en not_active Ceased
- 2007-03-05 CA CA002647258A patent/CA2647258A1/en not_active Abandoned
- 2007-03-05 JP JP2009503119A patent/JP2009532372A/ja active Pending
- 2007-03-05 US US12/294,530 patent/US8338480B2/en not_active Expired - Fee Related
- 2007-03-05 NZ NZ571118A patent/NZ571118A/en not_active IP Right Cessation
- 2007-03-05 CN CNA2007800110442A patent/CN101410105A/zh active Pending
-
2008
- 2008-09-17 IL IL194189A patent/IL194189A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009532372A5 (https=) | ||
| ES2522291T3 (es) | Agente activador para el receptor activado por el proliferador de peroxisomas | |
| JP2022096662A5 (https=) | ||
| JP2010501010A5 (https=) | ||
| JP2004529174A5 (https=) | ||
| AU2007235145B2 (en) | Combination treatment of metabolic disorders | |
| US8022063B2 (en) | CRTH2 receptor ligands for medicinal uses | |
| JP2023156479A5 (https=) | ||
| JP2009531280A5 (https=) | ||
| JP2013519680A5 (https=) | ||
| JP2010506825A5 (https=) | ||
| HRP20140335T1 (hr) | Derivati amino-piridina kao agonisti s1p1/edg1-receptora | |
| JP2009528275A5 (https=) | ||
| JP2007511485A5 (https=) | ||
| JP2010539152A5 (https=) | ||
| RU2006142746A (ru) | Индолилпроизводные в качестве модуляторов печеночного х-рецептора | |
| JP2019517455A5 (https=) | ||
| JP2008513499A5 (https=) | ||
| CN1503786A (zh) | 高传导率钙-活化k通道开启剂 | |
| JP2004509084A5 (https=) | ||
| JP2010513397A5 (https=) | ||
| JP2012502957A5 (https=) | ||
| CA2513092A1 (en) | Compounds for the treatment of metabolic disorders | |
| CN1703407A (zh) | 脂肪酸酰胺水解酶抑制剂 | |
| CA2607848A1 (en) | 3-substituted (3-phenyl)-propionic acid derivatives for the treatment of metabolic disorders |